限制围手术期静脉氯化物对心脏手术患者肾损伤的影响:LICRA实用性对照临床试验
该单中心实用性对照临床试验于2014年2月至2015年12月纳入1136例成人心脏手术患者,按四个连续5个月时段交替采用氯化物丰富策略(0.9%生理盐水与4%白蛋白,第1和第4时段)与氯化物限制策略(缓冲盐溶液与20%白蛋白,第2和第3时段)。主要终点为术后5天内峰值ΔSCr和KDIGO定义的2期或3期AKI。调整预设协变量后,氯化物丰富策略与峰值ΔSCr无关联(回归系数0.03,95%CI -0.03至0.08,P=0.39),与2期或3期AKI也无关联(调整OR 0.97,95%CI 0.65-1.47,P=0.90)。结论认为限制静脉氯化物策略未改变成人心脏手术患者的AKI发生率或其他肾损伤指标。
要点
- 成人心脏手术患者中,氯化物丰富策略与氯化物限制策略相比,术后5天内2期或3期AKI无显著差异(调整OR 0.97,95%CI 0.65-1.47,P=0.90)。
- 峰值ΔSCr在两种策略间无显著差异(回归系数0.03,95%CI -0.03至0.08,P=0.39)。
- 研究纳入1136例患者,氯化物丰富组569例,氯化物限制组567例。
- 围手术期方案覆盖从麻醉开始至ICU出院期间的所有液体管理。
- 作者结论:限制静脉氯化物策略未改变AKI发生率或其他肾损伤指标。
适用人群与场景
- 单中心成人心脏手术患者,从麻醉开始至ICU出院期间接受研究方案规定的静脉液体管理。
- 研究时段为2014年2月至2015年12月。
诊断标准与关键阈值
- 主要终点之一:术后5天内KDIGO定义的2期或3期急性肾损伤(AKI)。
- 主要终点之一:术后5天内峰值ΔSCr。
处置流程与药物剂量
- 氯化物丰富策略(第1和第4时段):使用0.9%生理盐水与4%白蛋白。
- 氯化物限制策略(第2和第3时段):使用缓冲盐溶液与20%白蛋白。
- 围手术期方案管理从麻醉开始至ICU出院期间的所有液体输注。
研究设计与关键结果
- 研究类型:单中心实用性对照临床试验,四个连续5个月时段交替采用两种液体策略,共纳入并分析1136例患者。
- 分组:氯化物丰富策略组569例,氯化物限制策略组567例。
- 主要终点:氯化物丰富策略与峰值ΔSCr无关联(回归系数0.03,95%CI -0.03至0.08,P=0.39),与KDIGO 2期或3期AKI无关联(调整OR 0.97,95%CI 0.65-1.47,P=0.90)。
- 结论:限制静脉氯化物策略未改变AKI发生率或其他肾损伤指标。
证据类型、等级与局限
- 证据类型:实用性对照临床试验。
- 试验注册:Clinicaltrials.gov标识符NCT02020538。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在成人心脏手术患者中,围手术期限制静脉氯化物策略未改变AKI发生率或其他肾损伤指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The administration of chloride-rich intravenous (IV) fluid and hyperchloraemia have been associated with perioperative renal injury. The aim of this study was to determine whether a comprehensive perioperative protocol for the administration of chloride-limited IV fluid would reduce perioperative renal injury in adults undergoing cardiac surgery.
METHODS: From February 2014 through to December 2015, all adult patients undergoing cardiac surgery within a single academic medical center received IV fluid according to the study protocol. The perioperative protocol governed all fluid administration from commencement of anesthesia through to discharge from the intensive care unit and varied over four sequential periods, each lasting 5 months. In periods 1 and 4 a chloride-rich strategy, consisting of 0.9% saline and 4% albumin, was adopted; in periods 2 and 3, a chloride-limited strategy, consisting of a buffered salt solution and 20% albumin, was used. Co-primary outcomes were peak delta serum creatinine (∆SCr) within 5 days after the operation and KDIGO-defined stage 2 or stage 3 acute kidney injury (AKI) within 5 days after the operation.
RESULTS: We enrolled and analysed data from 1136 patients, with 569 patients assigned to a chloride-rich fluid strategy and 567 to a chloride-limited one. Compared with a chloride-limited strategy and adjusted for prespecified covariates, there was no association between a chloride-rich perioperative fluid strategy and either peak ∆S Cr, transformed to satisfy the assumptions of multivariable linear regression [regression coefficient 0.03, 95% confidence interval (CI) -0.03 to 0.08); p = 0.39], or stage 2 or 3 AKI (adjusted odds ratio 0.97, 95% CI 0.65-1.47; p = 0.90].
CONCLUSIONS: A perioperative fluid strategy to restrict IV chloride administration was not associated with an altered incidence of AKI or other metrics of renal injury in adult patients undergoing cardiac surgery.
TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT02020538.
参考来源
- McIlroy D, Murphy D, Kasza J, et al. Effects of restricting perioperative use of intravenous chloride on kidney injury in patients undergoing cardiac surgery: the LICRA pragmatic controlled clinical trial. Intensive Care Med. 2017. PMID: 28343236. doi:10.1007/s00134-017-4772-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。